New combo therapy aims to stop upper tract cancer from coming back

NCT ID NCT06210490

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 02, 2026 · Updated 15 times

Summary

This study tests whether combining the drug disitamab vedotin with radiation therapy can help prevent upper urinary tract cancer from returning after surgery. It includes 60 patients whose tumors have high HER2 levels and who are at high risk for recurrence. Participants choose to receive the drug for 6 months plus radiation, or to be closely watched without extra treatment. The goal is to see if the combo improves how long patients stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER URINARY TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China

Contact

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

UPPER URINARY TRACT UROTHELIAL CARCINOMA